These data suggest that the difference in the inhibitory effects of Dex and the SEGRAs CpdA and ZK216348 on wound closure might be a result of their different interference with the EGF/ERK1/2/MAPK pathway, again pointing towards a clear advantage for SEGRAs in IBD treatment. Here, EGF is linked to inflammatory bowel disease.